Search

Biofortification is a revolutionary technique for improving plant nutrition and alleviating human micronutrient deficiency. Fertilizers can help increase crop yield and growth, but applying too much fertilizer can be a problem because it leads to the release of greenhouse gases and eutrophication. One of the major global hazards that affects more than two million people globally is the decreased availability of micronutrients in food crops, which results in micronutrient deficiencies or "hidden hunger" in people. Micronutrients, like macronutrients, perform a variety of roles in plant and human nutrition. This review has highlighted the importance of micronutrients as well as their advantages. The uneven distribution of micronutrients in geological areas is not the only factor responsible for micronutrient deficiencies, other parameters including soil moisture, temperature, texture of the soil, and soil pH significantly affects the micronutrient concentration and their availability in the soil. To overcome this, different biofortification approaches are assessed in the review in which microbes mediated, Agronomic approaches, Plant breeding, and transgenic approaches are discussed. Hidden hunger can result in risky health conditions and diseases such as cancer, cardiovascular disease, osteoporosis, neurological disorders, and many more. Microbes-mediated biofortification is a novel and promising solution for the bioavailability of nutrients to plants in order to address these problems. Biofortification is cost effective, feasible, and environmentally sustainable. Bio-fortified crops boost our immunity, which helps us to combat these deadly viruses. The studies we discussed in this review have demonstrated that they can aid in the alleviation of hidden hunger.

An accurate creatinine (Cr) estimate is pivotal for the assessment of renal function. Both patient- and practice-spawned factors palliate the test accuracy of serum creatinine (sCr) and can erratically represent actual kidney function. This study evaluated the caregivers’ awareness of enzymatic serum creatinine (E-sCr) assay interfering in dopamine/dobutamine (DD)-infused patient samples and the frequency of such interference in a critical care setting. We conducted an sCr awareness survey among UT Southwestern physicians, nurses, and pharmacists. We then performed a cross-sectional E-sCr comparison against the kinetic Jaffe method using the DD-infused patient samples collected from central venous catheters (CVC), peripherally inserted central catheter (PICC) lines, and the peripheral vein (PV). We retrospectively compared the longitudinal E-sCr results of the CVC/PICC draws with the corresponding blood urea nitrogen (BUN) levels. The survey results show a significant lack of awareness among caregivers about the negative interference of DD infusions on E-sCr. Cross-sectional E-sCr assessment relative to the Jaffe method displayed a negative interference in 12% of CVC/PICC line samples (7/57 DD-infused patients) compared to none in the PV draws. A longitudinal assessment of E-sCr, BUN, and potassium (K) levels from CVC/PICC line samples further confirmed a spurious decrease for E-sCr in about 12/50 (24%) patients who did not show a concurrent BUN or K decrease. The results suggest that a direct PV sampling accompanied by clinical laboratory-directed proactive discussion/activities can foster awareness among caregivers and eschew the false E-sCr estimates in DD-infused patients.

Aerial oxygen stereoselectively converts 5-hexenols into 2-methyltetrahydropyrans via oxidative cyclization/radical functionalization cascades, when activated by a fluoro-substituted cobalt(II) bis-(β-diketonate) complex in solutions of cyclohexa-1,4-diene (CHD).

Sera from 13 of 14 children with acute haemolytic uraemic syndrome (HUS) contained complement-fixing IgG and IgM antibodies that lysed cultured human umbilical vein endothelial cells. In 3 of 3 sera tested, no lysis of dermal fibroblasts was observed. The endothelial cell antigen was lost after treatment of the cells with gamma interferon. In contrast, only 3 of 5 adult patients with acute, non-relapsing, thrombotic thrombocytopenic purpura (TTP) had lytic anti-endothelial antibodies and only 1 of these recognised an antigen lost upon gamma interferon treatment. None of 32 control sera contained lytic anti-endothelial cell antibodies. These data suggest that HUS involves a disorder of immunoregulation and that a unique class of anti-endothelial cell antibodies is produced that may take part in the pathogenesis of vascular injury in HUS.